Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haemonetics ( (HAE) ) has shared an announcement.
On July 24, 2025, Haemonetics Corporation held its Annual Meeting of Shareholders, achieving a quorum with 94.95% of shares represented. During the meeting, shareholders elected nine directors for one-year terms, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending March 28, 2026.
The most recent analyst rating on (HAE) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page.
Spark’s Take on HAE Stock
According to Spark, TipRanks’ AI Analyst, HAE is a Outperform.
Haemonetics’ strong financial performance and positive earnings call guidance are significant strengths, driving the overall score. Technical analysis indicates a robust market position, though the valuation suggests a moderately priced stock. Challenges in certain segments, like the CSL transition, are noteworthy but do not overshadow the company’s overall positive trajectory.
To see Spark’s full report on HAE stock, click here.
More about Haemonetics
Haemonetics Corporation operates in the healthcare industry, providing blood management solutions. The company focuses on products and services that enhance blood collection, processing, and transfusion, catering to hospitals and blood centers globally.
Average Trading Volume: 563,800
Technical Sentiment Signal: Buy
Current Market Cap: $3.57B
Learn more about HAE stock on TipRanks’ Stock Analysis page.